Back

Characterising the 2023 chikungunya outbreak in Paraguay and the potential impact of a vaccine campaign

Perez-Estigarribia, P. E.; Ribeiro dos Santos, G.; Cauchemez, S.; Vazquez, C.; Ibarrola-Vannucci, A. K.; Sequera, G.; Villalba, S.; Jose Ortega, M.; Luis Di Fabio, J.; Scarponi, D.; Mukandavire, C.; Deol, A.; Cabello, A.; Vargas, E.; Fernandez, C.; Leon, L.; Salje, H.

2024-12-05 public and global health
10.1101/2024.12.02.24318291 medRxiv
Show abstract

There now exists a licensed chikungunya vaccine, however, it remains unclear if it could be deployed during outbreaks to reduce the health burden. We used an epidemic in Paraguay as a case study. We conducted a seroprevalence study and used models to reconstruct epidemic transmission dynamics, providing a framework to assess the theoretical impact of a vaccine had it been available. We estimated 33.0% (95% CI: 30.1-36.0) of the population became infected during the outbreak, 6.3% (95%CI: 5.8-6.9) of which were detected by the surveillance system, with a mean infection fatality ratio of 0.013 % (95%CI: 0.012-0.014). A disease-blocking vaccine with 75% efficacy deployed in 40% of > 12-year-olds over a three-month period would have prevented 34,200 (95% CI: 30,900-38,000) cases, representing 23% of cases, and 73 (95%CI: 66-81) deaths. If the vaccine also leads to infection blocking, 88% of cases would have been averted. These findings suggest the vaccine is an important new tool to control outbreaks.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.